Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5197)	12/21/2001 9:36:46 AM
From: scaram(o)uche	Respond to of 52153

would hire "would" as in past tense? Aren't they still doing it? INCR, recently.

To: Biomaven who wrote (5197)	12/21/2001 9:43:27 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 52153

WRT valuation, I think Elan is looking pretty compelling. They have a great pipeline; good drug delivery technology; loads of joint ventures and biotech investments that appear to be bearing fruit; strong financials (including good earnings.) There has been some harping on quality of earnings, but I think that issue is gone since the mechanism Peter cited makes up a very small percentage of revenues. The recent news flow has been excellent (Antegren in PIII trials and Sonata deal with AHP.) Is expected to earn about $2.30 next year. Any opinions?